Literature DB >> 7679293

Clonal growth of functionally normal and deficient neutrophils from the bone marrow of a patient with variant chronic granulomatous disease. Lack of reconstitution of oxidative burst defect by G-CSF, GM-CSF, and IFN-gamma in vitro.

S Oez1, J Birkmann, J R Kalden.   

Abstract

To evaluate the effect of colony-stimulating factors and interferon gamma on the oxidative burst capacity of neutrophils in chronic granulomatous disease (CGD) we studied the neutrophils of a patient with variant CGD both from peripheral blood and from bone marrow culture on day 7 and 14. The results revealed that preincubation of peripheral neutrophils for 24 h in medium containing recombinant human granulocyte colony-stimulating factor (rhG-CSF), recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF), and recombinant human interferon gamma (rhIFN-gamma) alone or in combination did not improve the maximal oxidative burst activity measured by MTT assay. The colonies of this patient formed in agar assay were either composed of predominantly nitroblue tetrazolium (NBT)-positive cells or completely unable to reduce NBT. Despite variable colony numbers in the presence of different cytokines, the rate of NBT-positive colonies was less than 17% of the total number of colonies. However, more than 72% of the colonies were NBT positive in controls. In liquid culture, bone marrow cells yielded a comparable rate of NBT-positive and -negative populations at day 7. These data indicate that rhG-CSF, rhGM-CSF, and rhIFN-gamma alone or rhG-CSF and rhGM-CSF in combination with rhIFN-gamma are not able to reconstitute the oxidative burst defect in CGD in vitro. Indeed, regarding colony-forming capacity, the bone marrow cells from the patient responded to CSFs as well as those from control donors did. This fact may warrant the administration of hematopoietic growth factors, at least in variant CGD, in order to enhance the absolute number of functionally normal neutrophils.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679293     DOI: 10.1007/bf01737685

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  22 in total

1.  Gene deletion in a patient with chronic granulomatous disease and McLeod syndrome: fine mapping of the Xk gene locus.

Authors:  D Frey; M Mächler; R Seger; W Schmid; S H Orkin
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

2.  A variant of chronic granulomatous disease: deficient oxidative metabolism due to a low-affinity NADPH oxidase.

Authors:  P D Lew; F S Southwick; T P Stossel; J C Whitin; E Simons; H J Cohen
Journal:  N Engl J Med       Date:  1981-11-26       Impact factor: 91.245

3.  Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies.

Authors:  J Nemunaitis; J W Singer; C D Buckner; R Hill; R Storb; E D Thomas; F R Appelbaum
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

4.  Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.

Authors:  R Repp; T Valerius; A Sendler; M Gramatzki; H Iro; J R Kalden; E Platzer
Journal:  Blood       Date:  1991-08-15       Impact factor: 22.113

5.  Variant chronic granulomatous disease: modulation of the neutrophil defect by severe infection.

Authors:  P E Newburger; F W Luscinskas; T Ryan; C J Beard; J Wright; O S Platt; E R Simons; A I Tauber
Journal:  Blood       Date:  1986-10       Impact factor: 22.113

6.  Genetic variants of chronic granulomatous disease: prevalence of deficiencies of two cytosolic components of the NADPH oxidase system.

Authors:  R A Clark; H L Malech; J I Gallin; H Nunoi; B D Volpp; D W Pearson; W M Nauseef; J T Curnutte
Journal:  N Engl J Med       Date:  1989-09-07       Impact factor: 91.245

7.  Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity.

Authors:  R C Woodman; R W Erickson; J Rae; H S Jaffe; J T Curnutte
Journal:  Blood       Date:  1992-03-15       Impact factor: 22.113

Review 8.  Chronic granulomatous disease: a syndrome of phagocyte oxidase deficiencies.

Authors:  A I Tauber; N Borregaard; E Simons; J Wright
Journal:  Medicine (Baltimore)       Date:  1983-09       Impact factor: 1.889

9.  Synergistic inhibition of human marrow granulocyte-macrophage progenitor cells by prostaglandin E and recombinant interferon-alpha, -beta, and -gamma and an effect mediated by tumor necrosis factor.

Authors:  L M Pelus; O G Ottmann; K H Nocka
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

10.  Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.

Authors:  M H Bronchud; J H Scarffe; N Thatcher; D Crowther; L M Souza; N K Alton; N G Testa; T M Dexter
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

View more
  4 in total

Review 1.  Reactive oxygen species in phagocytic leukocytes.

Authors:  John M Robinson
Journal:  Histochem Cell Biol       Date:  2008-07-03       Impact factor: 4.304

Review 2.  The NADPH oxidase complex of phagocytic leukocytes: a biochemical and cytochemical view.

Authors:  J M Robinson; J A Badwey
Journal:  Histochem Cell Biol       Date:  1995-03       Impact factor: 4.304

3.  Neutrophil swarming delays the growth of clusters of pathogenic fungi.

Authors:  Alex Hopke; Allison Scherer; Samantha Kreuzburg; Michael S Abers; Christa S Zerbe; Mary C Dinauer; Michael K Mansour; Daniel Irimia
Journal:  Nat Commun       Date:  2020-04-27       Impact factor: 14.919

Review 4.  Raising the 'Good' Oxidants for Immune Protection.

Authors:  Alexia Dumas; Ulla G Knaus
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.